Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

ClinicalTrials.gov ID: NCT01563536

Public ClinicalTrials.gov record NCT01563536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Study identification

NCT ID
NCT01563536
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
12 participants

Conditions and interventions

Interventions

  • ABT-267 Drug
  • ABT-450 Drug
  • ABT-333 Drug
  • Ritonavir Drug
  • Ribavirin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2012
Primary completion
Mar 31, 2012
Completion
May 31, 2013
Last update posted
Jul 1, 2018

2012 – 2013

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Site Reference ID/Investigator# 68002 Bakersfield California 93301
Site Reference ID/Investigator# 67383 Orlando Florida 32809
Site Reference ID/Investigator# 67382 Annapolis Maryland 21401
Site Reference ID/Investigator# 67385 Poughkeepsie New York 12601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01563536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2018 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01563536 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →